The MarketReader Minute
đź’Š Biotech Sector Slips as Gilead Faces $202M Settlement, CPI Fuels Inflation Worries | Biotech Sector Insights
(IBB) declined, echoing broader risk-off sentiment after U.S. CPI data showed a 2.7% annual rise above the Fed’s target and amid tariff concerns raised by President Trump. IBB holdings, including Regeneron, Moderna, and Vertex, also traded lower in Tuesday’s session.